CLDN1 and thyroid cancer, nonmedullary, 2: Downregulation of claudin-1 with various strategies, including PKC inhibition, C. perfringens enterotoxin, RET inhibition, or exogenic delivery of anti-cancer miRNA, may be beneficial in the case of PTC, FTC, and MTC.